Abstract
Antibody-drug conjugates (ADCs) are promising biotherapeutics designed to selectively deliver highly cytotoxic drugs to tumor cells while sparing normal tissues. They can be viewed as prodrugs, stable in the bloodstream in order to minimize drug release in circulation and efficiently converted into active drugs in the tumor tissues. Designing the right combination of monoclonal antibody (mAb), linker and drug, requires monitoring and understanding the behavior of all three components in the bloodstream and tumor. In particular, linkers have been shown to influence efficacy and safety profiles of ADCs, and monitoring in vivo “drug-linker stability” is therefore critical to help the linker choice and is performed by identifying the pharmacokinetics (PK) profiles. PK properties of ADCs are measured by following the profiles of three entities: (a) the conjugate (mAb entity carrying at least one drug), (b) the total antibody (mAb entity regardless of drug load), as well as (c) the free drugs and metabolites entities. This chapter focuses on the key analytical methods (ELISA immunoassays, TFC-MS/MS, and HRMS) used to support the PK profiles assessment of the three entities, allowing the characterization of ADC “drug-linker stability”.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137–1146
Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5:543–549
Kratz F, Müller IA, Ryppa C, Warnecke A (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem 3:20–53
Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies—mechanistic modeling applied to drug development. Curr Opin Drug Discov Dev 10(1):84–96
Carter PJ, Senter PD (2008) Antibody–drug conjugates for cancer therapy. Cancer J 14:154–169
Stephan JP, Kozak KR, Wong WL (2011) Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates. Bioanalysis 3(6):677–700
Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I (2002) An anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40–46
Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212–215
Chari RVJ (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98–107
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res 68:9280–9290
Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711–760
Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM (2011) SAR3419: an anti-CD19-Maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 17(20):6448–6458
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC (2009) The monoclonal antibody nBT062conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15:4028–4037
Erickson HK, Lambert JM (2012) ADME of antibody–maytansinoid conjugates. AAPS J 14(4):799–805
Koblinski JE, Ahram M, Sloane BF (2000) Unravelling the role of proteases in cancer. Clin Chim Acta 291:113–135
U.S. Food and Drug Administration (2011) FDA approves adcetris to treat two types of lymphoma, for immediate release: 19 Aug 2011. U.S. Food and Drug Administration, Silver Spring, MD, 20993
Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784
Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426–4433
Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX (2010) Engineered thio-trastuzumab–DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16(19):4769–4778
Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, Scheller RH, Lowman HB (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 332:41–52
Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W (2005) Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14:2436–2446
Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26(8):925–932
Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29(9):2354–2366
Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons- Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody drug conjugates. Nat Biotechnol 30:184–189
Baker MA, Roncari DAK, Taub RN, Mohanakumar T, Falk JA, Grant S (1982) Characterization of compounds shed from the surface of human leukemic myeloblasts in vitro. Blood 60:412–419
Black PH (1980) Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32:75–199
Lu Y, Wong WL, Meng YG (2006) A high throughput electrochemiluminescent cell-binding assay for therapeutic anti-CD20 antibody selection. J Immunol Methods 314:74–79
Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11:843–852
Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A (2008) Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 19(8):1673–1683
Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, Song A (2012) The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: case studies. MAbs 4(5):623–631
Acknowledgements
The authors would like to greatly thank Patrick Verdier, Marie-Hélène Pascual, and Olivier Pasquier for providing their lab protocols, for their constructive input, and careful review of this chapter. The authors are grateful to Ingrid Sassoon and Veronique Blanc for giving high-level background and critical reading of the manuscript. We also thank Delphine Valente, Christine Mauriac, Gerard Sanderink, and John Newton for giving relevant review and their support.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Abecassis, PY., Amara, C. (2013). In Vivo Testing of Drug-Linker Stability. In: Ducry, L. (eds) Antibody-Drug Conjugates. Methods in Molecular Biology, vol 1045. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-541-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-62703-541-5_6
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-540-8
Online ISBN: 978-1-62703-541-5
eBook Packages: Springer Protocols